

1544/\$

Docket No. PRD-48USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Chen, X. et al.

Serial No. : 10/688,380

Art Unit: 1641

Filed : October 17, 2003

Examiner: Not yet assigned

For : TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND
INDANES

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

2-17-05

(Date of Deposit)

Jeremy K. McKown

(Name of applicant, assignee, or Registered Representative)

J K McKown
(Signature)

2/17/05

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure
Statement mailed on March 2, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37
C.F.R. §§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

Applicant(s) reserve(s) the right to establish the
patentability of the claimed invention over any of the
information provided herewith, and/or to prove that this
information may not be prior art, and/or to prove that this

02/25/2005 AWONDAF1 00000102 100750 10688380

01 FC:1806

180.00 DA

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☒ Please charge Deposit Account No. 10-0750/PRD48USNP/JKM the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are not enclosed herewith. **Please see Serial No. 10/688,379 for references.**

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e)
(attached); or

☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☐ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.


Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-48USNP/JKM. This form is submitted in triplicate.

Respectfully submitted,



Jeremy K. McKown
Reg. No. 47,785
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6250
DATED: 2/17/05



PTO/SB/08A (08-00)
 Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary) Sheet 1 of 2</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;">Application Number</td> <td style="padding: 2px;">10/688,380</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">October 17, 2003</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Xiaoli, C.</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">1641</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">To be Assigned</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">PRD-48USNP</td> </tr> </table>	Application Number	10/688,380	Filing Date	October 17, 2003	First Named Inventor	Xiaoli, C.	Group Art Unit	1641	Examiner Name	To be Assigned	Attorney Docket Number	PRD-48USNP
Application Number	10/688,380												
Filing Date	October 17, 2003												
First Named Inventor	Xiaoli, C.												
Group Art Unit	1641												
Examiner Name	To be Assigned												
Attorney Docket Number	PRD-48USNP												

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		6,028,109		Glaxo Wellcome Inc.	02-22-2000	
		6,306,854	B1	Glaxosmithkline	10-23-2001	
		6,750,236	B2	Bayer Aktiengesellschaft	06-15-2004	
		(eq. to WO/02/28821)				

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
		EP	399422	A1	Takeda Chemical Industries	11-28-1990		
		WO	92/10468	A1	The Wellcome Foundation Ltd.	06-25-1992		
		WO	95/04713	A1	The Upjohn Co.	02-16-1995		
		WO	02/28821	A2	Bayer Aktiengesellschaft	04-11-2002	(U.S. eq. 6,750,236)	
		WO	02/064549	A1	Pfizer Products Inc.	08-22-2002		
		WO	02/064146	A1	Aventis Pharma Deutschland GMBH	08-22-2002		

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 2

Application Number	10/688,380
Filing Date	October 17, 2003
First Named Inventor	Xiaoli, C.
Group Art Unit	1641
Examiner Name	Not yet assigned
Attorney Docket Number	PRD-49USNP

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.